Endpoints News Feb 24, 2026 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
BioPharma Dive Feb 23, 2026 Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Endpoints News Feb 23, 2026 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
PharmaVoice Feb 12, 2026 Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
BioPharma Dive Feb 9, 2026 Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals
FierceBiotech Feb 9, 2026 Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'